Retinoblastoma - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 55
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R485B8F0FB5EN
Leaflet:

Download PDF Leaflet

Retinoblastoma - Pipeline Review, H2 2017
Retinoblastoma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Pipeline Review, H2 2017, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Retinoblastoma - Overview
Retinoblastoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Retinoblastoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoblastoma - Companies Involved in Therapeutics Development
Icon Bioscience Inc
Innovation Pharmaceuticals Inc
Ophthotech Corp
PepVax Inc
Recombio SL
VCN Biosciences SL
Retinoblastoma - Drug Profiles
FL-761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kevetrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melphalan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nutlin-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegpleranib sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
racotumomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinoblastoma - Dormant Projects
Retinoblastoma - Product Development Milestones
Featured News & Press Releases
Jul 26, 2017: Ophthotech Announces Update on Fovista
Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01
Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Retinoblastoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Retinoblastoma - Pipeline by Icon Bioscience Inc, H2 2017
Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Retinoblastoma - Pipeline by Ophthotech Corp, H2 2017
Retinoblastoma - Pipeline by PepVax Inc, H2 2017
Retinoblastoma - Pipeline by Recombio SL, H2 2017
Retinoblastoma - Pipeline by VCN Biosciences SL, H2 2017
Retinoblastoma - Dormant Projects, H2 2017

LIST OF FIGURES

Number of Products under Development for Retinoblastoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Icon Bioscience Inc
Innovation Pharmaceuticals Inc
Ophthotech Corp
PepVax Inc
Recombio SL
VCN Biosciences SL
Skip to top


Ask Your Question

Retinoblastoma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: